Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/19/2025 16:12 PDT] Contineum Therapeutics, Inc. (NASDAQ:ctnm), Up By 100% ($3.94) From $3.94 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/16/2025 07:14 PDT] ctnm Expected to Trade Up After Bullish Patterns Develop
• [04/11/2025 13:58 PDT] Contineum Therapeutics, Inc. (NASDAQ:ctnm), Down By 100% ($4.62) From $4.62 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/10/2025 07:37 PDT] ctnm Expected to Trade Down After Bearish Patterns Develop